Collagen-binding Molecular Chaperone HSP47: Role in Intestinal Fibrosis – colonic epithelial cells and subepithelial myofibroblasts
Curators: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
De novo design based pharmacophore query generation and virtual screening for the discovery of Hsp-47 inhibitors.
Katarkar A1, Haldar PK2, Chaudhuri K3.
Abstract
Heat shock protein-47 (Hsp-47) is exclusive collagen specific molecular chaperone involved in the maturation, processing and secretion of procollagen. Hsp-47 is consistently upregulated in several fibrotic diseases. Till date there is no potential antifibrotic small molecule drug available and Hsp-47 is known to be potential therapeutic target for fibrotic disorder and drug designing. We used the de novo drug design approach followed by pharmacophore generation and virtual screening to propose Hsp-47 based antifibrotic molecules. We used e-LEAD server for de novo drug design and ZINCPharmer for 3D pharmacophore generation and virtual screening. The virtually screened molecule may inhibit direct recruitment of collagen triple helix to interact with Hsp-47 and act as antifibrotic drug.
Copyright © 2014 Elsevier Inc. All rights reserved.
KEYWORDS:
De novo drug designing; Heat shock protein 47; Pharmacophore; Virtual screening
REFERENCES
|
1. |
|
|
Honzawa Y, Nakase H, Shiokawa M, Yoshino T, Imaeda H, Matsuura M, Kodama Y, Ikeuchi H, Andoh A, Sakai Y, Nagata K, Chiba T. |
|
|
Gut. 2014 Dec;63(12):1902-12. doi: 10.1136/gutjnl-2013-305632. Epub 2014 Feb 17. |
|
|
PMID: 24534724 [PubMed – indexed for MEDLINE] |
|
|
2. |
Role of heat shock protein 47 in intestinal fibrosis of experimental colitis. |
|
Kitamura H, Yamamoto S, Nakase H, Matsuura M, Honzawa Y, Matsumura K, Takeda Y, Uza N, Nagata K, Chiba T. |
|
|
Biochem Biophys Res Commun. 2011 Jan 14;404(2):599-604. doi: 10.1016/j.bbrc.2010.12.006. Epub 2010 Dec 6. |
|
|
PMID: 21144841 [PubMed – indexed for MEDLINE] |
|
|
3. |
|
|
Abe K, Ozono Y, Miyazaki M, Koji T, Shioshita K, Furusu A, Tsukasaki S, Matsuya F, Hosokawa N, Harada T, Taguchi T, Nagata K, Kohno S. |
|
|
Nephrol Dial Transplant. 2000 Apr;15(4):529-35. |
|
|
PMID: 10727549 [PubMed – indexed for MEDLINE] Free Article |
|
|
4. |
|
|
Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, Harada T, Ozono Y, Koji T, Kohno S. |
|
|
Kidney Int. 2003 Sep;64(3):887-96. |
|
|
PMID: 12911538 [PubMed – indexed for MEDLINE] |
|
|
5. |
Involvement of heat shock protein 47 in Schistosoma japonicum-induced hepatic fibrosis in mice. |
|
Huang JQ, Tao R, Li L, Ma K, Xu L, Ai G, Fan XX, Jiao YT, Ning Q. |
|
|
Int J Parasitol. 2014 Jan;44(1):23-35. doi: 10.1016/j.ijpara.2013.08.009. Epub 2013 Dec 1. |
|
|
PMID: 24295791 [PubMed – indexed for MEDLINE] |
|
|
6. |
The collagen-specific molecular chaperone HSP47: is there a role in fibrosis? |
|
Taguchi T, Razzaque MS. |
|
|
Trends Mol Med. 2007 Feb;13(2):45-53. Epub 2006 Dec 13. |
|
|
PMID: 17169614 [PubMed – indexed for MEDLINE] |
|
|
7. |
|
|
Truchetet ME, Brembilla NC, Montanari E, Lonati P, Raschi E, Zeni S, Fontao L, Meroni PL, Chizzolini C. |
|
|
Arthritis Rheum. 2013 May;65(5):1347-56. doi: 10.1002/art.37860. |
|
|
PMID: 23335253 [PubMed – indexed for MEDLINE] Free Article |
|
|
8. |
|
|
Li Y, Wu W, Jiang YF, Wang KK. |
|
|
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2007 Aug;32(4):650-5. Chinese. |
|
|
PMID: 17767059 [PubMed – indexed for MEDLINE] Free Article |
|
|
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.